Posts by: Ana Pamplona, PhD

Ana Pamplona, PhD

Ana holds her PhD in Biochemistry from the Faculty of Science and Technology from Lisbon (UNL). She has worked in the T-cell differentiation and Tumor targeting Lab at Instituto de Medicina Molecular, headed by Prof. Bruno Silva-Santos, and has served as a scientific reviewer for the peer-reviewed journal Infection & Immunity.

October 10, 2014October 10, 2014

Grapefruit Juice Lowers Glucose the same as Metformin in New Study

News, Type 2 Diabetes News

A new study, entitled “Consumption of Clarified Grapefruit Juice Ameliorates High-Fat Diet Induced Insulin Resistance and Weight Gain in Mice” was published in the peer-reviewed journal PLOS ONE by Dr. ... Read more

October 7, 2014October 7, 2014

Childhood Diabetes May Be Triggered in Utero By Viral infection

News, Type 1 Diabetes News

A new study contributing to a better understanding of type 1 childhood diabetes, entitled “Antibodies to islet cell auto antigens, rotaviruses and/or enteroviruses in cord blood and healthy mothers in ... Read more

October 7, 2014October 7, 2014

Clues On How Type 2 Diabetes Develops Revealed Through Research Using Twins

News, Type 2 Diabetes News

A new study, entitled “Altered DNA methylation and differential expression of genes influencing metabolism and inflammation in adipose tissue from subjects with type 2 diabetes” published in the journal Diabetes by Dr. ... Read more

September 18, 2014September 19, 2014

Trulicity For Type 2 Diabetes Approved by FDA

News, Type 2 Diabetes News

Yesterday, the U.S. Food and Drug Administration (FDA) approved Trulicity (dulaglutide) as a new treatment for Type 2 diabetes in adults. The treatment will consist of subcutaneous injection, once per ... Read more

September 17, 2014September 17, 2014

New Insulin From Novo Nordisk Reveals Long-Term Efficacy in Both Children and Adolescents

News, Type 1 Diabetes News

Novo Nordisk released new data from the clinical trial, BEGIN YOUNG 1, a study comparing a once-daily Tresiba (insulin degludec) regime, an ultralong-acting basal insulin analogue, with an insulin detemir regime, ... Read more

September 11, 2014September 11, 2014

Lilly’s Basal Insulin Peglispro Outperforms Lantus® in HbA1c Superiority in Phase III Trials For Type 1 Diabetes

News, Type 1 Diabetes News

Eli Lilly and Company recently reported that its IMAGINE-1 and IMAGINE-3 Phase III clinical trials showed that basal insulin peglispro (BIL) treatment induces a statistically significant lower hemoglobin A1c (HbA1c, glycated haemoglobin), a ... Read more